215,830 Shares in Zenas BioPharma, Inc. $ZBIO Acquired by iA Global Asset Management Inc.

iA Global Asset Management Inc. bought a new position in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 215,830 shares of the company’s stock, valued at approximately $4,219,000. iA Global Asset Management Inc. owned 0.38% of Zenas BioPharma at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ZBIO. Quarry LP increased its stake in shares of Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Zenas BioPharma during the 3rd quarter valued at $30,000. GF Fund Management CO. LTD. bought a new position in Zenas BioPharma in the 4th quarter worth $38,000. BNP Paribas Financial Markets boosted its holdings in Zenas BioPharma by 120.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after buying an additional 1,716 shares during the period. Finally, CWM LLC increased its stake in Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after buying an additional 709 shares in the last quarter.

Zenas BioPharma Price Performance

NASDAQ:ZBIO opened at $28.00 on Thursday. The business’s 50-day moving average is $19.62 and its 200 day moving average is $23.06. Zenas BioPharma, Inc. has a 12 month low of $8.91 and a 12 month high of $44.60. The company has a market capitalization of $1.77 billion, a P/E ratio of -3.31 and a beta of -0.97. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same period in the prior year, the company posted ($0.80) earnings per share. On average, equities research analysts forecast that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current fiscal year.

Insider Transactions at Zenas BioPharma

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. acquired 60,000 shares of the company’s stock in a transaction on Monday, May 18th. The stock was acquired at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the purchase, the chief executive officer directly owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. This represents a 162.48% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have acquired a total of 120,000 shares of company stock worth $2,080,000 over the last quarter. 22.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZBIO. Morgan Stanley boosted their price objective on Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Zacks Research raised Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Finally, Guggenheim upped their price target on Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $44.29.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.